Sorafenib versus lenvatinib-based sequential systemic therapy for advanced hepatocellular carcinoma: a real-world analysis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: Cancers (2022) 14:8, 1975. https://doi.org/10.3390/cancers14081975
- Ereignis
-
Veröffentlichung
- (wo)
-
Würzburg
- (wer)
-
Universität Würzburg
- (wann)
-
2023
- Urheber
-
Leyh, Catherine
Ehmer, Ursula
Roessler, Daniel
Philipp, Alexander B.
Reiter, Florian P.
Jeliazkova, Petia
Jochheim, Leonie S.
Jeschke, Matthias
Hammig, Janina
Ludwig, Johannes M.
Theysohn, Jens M.
Geier, Andreas
Lange, Christian M.
- DOI
-
10.3390/cancers14081975
- URN
-
urn:nbn:de:bvb:20-opus-270765
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
25.03.2025, 13:49 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Leyh, Catherine
- Ehmer, Ursula
- Roessler, Daniel
- Philipp, Alexander B.
- Reiter, Florian P.
- Jeliazkova, Petia
- Jochheim, Leonie S.
- Jeschke, Matthias
- Hammig, Janina
- Ludwig, Johannes M.
- Theysohn, Jens M.
- Geier, Andreas
- Lange, Christian M.
- Universität Würzburg
Entstanden
- 2023
Ähnliche Objekte (12)
Sorafenib-Induced Apoptosis in Hepatocellular Carcinoma Is Reversed by SIRT1
Sorafenib resistance of hepatocellular carcinoma : antibiotics second-line to Sorafenib therapy inhibit mitochondrial biogenesis and prevent tumor growth resumption
Pancreatic Atrophy in Hepatocellular Carcinoma Patients Receiving Long-Term Treatment with Sorafenib
Sorafenib response in hepatocellular carcinoma therapy : introducing new possibilities with Cdk5 inhibition
Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study
Correction: Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study
Impact of NAFLD on clinical outcomes in hepatocellular carcinoma treated with sorafenib: an international cohort study
Improved survival prediction and comparison of prognostic models for patients with hepatocellular carcinoma treated with sorafenib
Tumor-treating fields concomitant with sorafenib in advanced hepatocellular cancer: results of the HEPANOVA Phase II Study
Sorafenib treatment and modulation of the sphingolipid pathway affect proliferation and viability of hepatocellular carcinoma In vitro
Tumor treating fields concomitant with sorafenib in advanced hepatocellular cancer: results of the HEPANOVA phase II study
Sorafenib : Sorafenib in der Behandlung des Radiojod-refraktären differenzierten Schilddrüsenkarzinoms
Sorafenib-Induced Apoptosis in Hepatocellular Carcinoma Is Reversed by SIRT1
Sorafenib resistance of hepatocellular carcinoma : antibiotics second-line to Sorafenib therapy inhibit mitochondrial biogenesis and prevent tumor growth resumption
Pancreatic Atrophy in Hepatocellular Carcinoma Patients Receiving Long-Term Treatment with Sorafenib
Sorafenib response in hepatocellular carcinoma therapy : introducing new possibilities with Cdk5 inhibition
Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study
Correction: Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study
Impact of NAFLD on clinical outcomes in hepatocellular carcinoma treated with sorafenib: an international cohort study
Improved survival prediction and comparison of prognostic models for patients with hepatocellular carcinoma treated with sorafenib
Tumor-treating fields concomitant with sorafenib in advanced hepatocellular cancer: results of the HEPANOVA Phase II Study
Sorafenib treatment and modulation of the sphingolipid pathway affect proliferation and viability of hepatocellular carcinoma In vitro
Tumor treating fields concomitant with sorafenib in advanced hepatocellular cancer: results of the HEPANOVA phase II study
Sorafenib : Sorafenib in der Behandlung des Radiojod-refraktären differenzierten Schilddrüsenkarzinoms
Sorafenib-Induced Apoptosis in Hepatocellular Carcinoma Is Reversed by SIRT1
Sorafenib resistance of hepatocellular carcinoma : antibiotics second-line to Sorafenib therapy inhibit mitochondrial biogenesis and prevent tumor growth resumption
Pancreatic Atrophy in Hepatocellular Carcinoma Patients Receiving Long-Term Treatment with Sorafenib
Sorafenib response in hepatocellular carcinoma therapy : introducing new possibilities with Cdk5 inhibition
Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study
Correction: Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study
Impact of NAFLD on clinical outcomes in hepatocellular carcinoma treated with sorafenib: an international cohort study
Improved survival prediction and comparison of prognostic models for patients with hepatocellular carcinoma treated with sorafenib
Tumor-treating fields concomitant with sorafenib in advanced hepatocellular cancer: results of the HEPANOVA Phase II Study
Sorafenib treatment and modulation of the sphingolipid pathway affect proliferation and viability of hepatocellular carcinoma In vitro
Tumor treating fields concomitant with sorafenib in advanced hepatocellular cancer: results of the HEPANOVA phase II study